This Play Could Double Again – But There's Much More to It

A big grin lit up my face when I opened my trading screens recently. I was looking at the chart for Ekso Bionics . The company was trading at right around $1.81 per share at midday on Monday. That means it was close to a double from where I initially recommended it as our first human augmentation target to members of my Total Wealth research service. Ekso is still a great buy, which is why I'm recommending it for Money Morning , too. There's plenty of room for this company to double - again. The post This Play Could Double Again – But There's Much More to It appeared first on Money Morning - Only the News You Can Profit From .